Allergic Bronchopulmonary Aspergillosis Therapeutics Market

Report Description

Allergic Bronchopulmonary Aspergillosis Therapeutics Market Outlook 2032

The global allergic bronchopulmonary aspergillosis therapeutics market size was USD XX Billion in 2023 and is likely to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed to the increasing incidence of COPD and Asthma, rising awareness among population regarding the fungi and their harmful effects, unmet medical needs, and the growing geriatric population.

Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disease caused by an allergic reaction to the Aspergillus fungus.

• In August 2023, an article published by the University of Chicago stated that Aspergillus allergy was found in around 25% of asthmatics and 50% of patients with cystic fibrosis; however, ABPA allergy is not as common. About 13% and 9% of people with cystic fibrosis and asthma, respectively, have ABPA. Worldwide, more than 4 million people are affected by ABPA.

Exposure to aspergillus has negative effects on individuals with strong immune systems. However, weak individuals and those with chronic lung conditions are at high risk. Patients undergoing chemotherapy or organ transplants also have compromised immune systems, leading to various types of aspergillus infections. Key players such as F2G, TFF Pharmaceuticals, Scynexis, and Pulmocide are upending long-standing pharmaceutical giants by launching cutting-edge therapeutic approaches that have the potential to transform the treatment of invasive aspergillosis.

ABPA is common in patients with cystic fibrosis, bronchiectasis, and asthma due to increased mucus in their airways. Symptoms of ABPA include uncontrolled hemoptysis, expectoration of mucus plugs, discomfort, and fever. ABPA is diagnosed using an IgE blood test, chest X-ray, skin prick test, positive sputum culture, and increased blood eosinophils count. The exact causes of these reactions remain unknown.

ABPA treatment becomes complicated with recurrent exacerbations and rapid remissions. Drugs such as glucocorticoids, antifungal agents, and biologics consist of numerous benefits as well as side effects. ABPA is managed using steroids and anti-fungal to prevent lung damage and reduce inflammation. Current oral dose regimens last up to 6 months. Oral azoles, the primary anti-fungal treatment, are prescribed to approximately 80% of ABPA patients. Itraconazole blocks ergosterol synthesis, limiting fungal growth and reproduction, resulting in toxic sterols.

Get Free Sample Report

Impact of Artificial Intelligence (AI) on the Allergic Bronchopulmonary Aspergillosis Therapeutics Market

Artificial intelligence has a great impact on the allergic bronchopulmonary aspergillosis therapeutics market. Artificial intelligence, when combined with drug discovery and drug targeting, introduces new drugs into the market. Furthermore, the combination of drugs and their resultant effects contribute to improved outcomes, hence driving the market. Telemedicine, offering easy access and interaction with specialists, is expected to drive the market by providing video consultations and homecare treatment.

Allergic Bronchopulmonary Aspergillosis Therapeutics Market Dynamics

Get Free Sample Report

Major Drivers

Rising prevalence of respiratory disorders, such as asthma and COPD, increasing incidence of allergic reaction due to foreign particles, and the growing R&D activities for drug discoveries are driving the market for allergic bronchopulmonary aspergillosis therapeutics.

Existing Restraints

Side effects such as glaucoma, hypertension, and nausea associated with certain medications, which are highly prescribed, including corticosteroids, are hindering the market.

Emerging Opportunities

­Growing advancements in targeted antifungals, the development of immunomodulatory therapies, emerging diagnostic tools, and convenience in healthcare by telehealth and remote monitoring offer lucrative opportunities in the market. The market is expected to offer effective and accessible solutions for patients living with ABPA by addressing current limitations and leveraging emerging trends.

Scope of the Allergic Bronchopulmonary Aspergillosis Therapeutics Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Allergic Bronchopulmonary Aspergillosis Therapeutics Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the allergic bronchopulmonary aspergillosis therapeutics market is divided into antibiotics, azoles, and corticosteroids. The corticosteroids segment held a large share of the market in 2023 and is anticipated to expand at a rapid pace in the coming years due to the growing use of corticosteroids as the main treatment option for ABPA. Steroids aid in the alleviation of symptoms, serum IgE, peripheral blood eosinophil, and airflow obstruction. Additionally, corticosteroids prevent irreversible lung damage and aid in the management of pulmonary infiltrates and inflammation. The first-line treatment for ABPA in both asthma and cystic fibrosis is corticosteroids.

The azole segment is expected to expand at a significant growth rate in the coming years due to its antifungal properties, which are used to reduce infection and prevent other associated fungal infections. Itraconazole is recommended as an add-on therapy for steroid-dependent patients, relapsing ABPA patients, and those who do not respond to oral steroids combined with inhaled corticosteroids.

Get Free Sample Report

Route of Administration Segment Analysis

On the basis of route of administration, the global allergic bronchopulmonary aspergillosis therapeutics market is segregated into oral, parenteral, and inhalation. The oral segment held a large market share in 2023 owing to the ease of administration of repeated dosage. Oral corticosteroids are the recommended course of treatment for allergic bronchopulmonary aspergillosis (ABPA).

The inhalation segment is anticipated to expand at a substantial CAGR during the forecast period. Inhaled corticosteroids (ICS) have few side effects to use in the treatment of ABPA. Several researches have proven amphotericin B inhalation as a supplement or alternative therapy. It directly targets the fungal infection in the respiratory system.

Treatment Segment Analysis

Based on treatment, the allergic bronchopulmonary aspergillosis therapeutics market is segmented into bronchodilators, antibiotics, embolization, vaccinations, corticosteroids, physiotherapies, and others. The corticosteroids segment dominated the market in terms of revenue in 2023. In addition to relieving symptoms, steroids reduce peripheral blood eosinophil counts, serum IgE levels, and airflow obstruction, thereby driving the segment.

Prednisolone is the drug which is largely been prescribed for treating ABPA due to its cost-effectiveness, convenience, and safety profile. For ABPA, systemic corticosteroids are the main treatment. Additionally, it resolves pulmonary infiltrates and inflammation, avoids irreparable lung damage, and reduces pulmonary inflammation.

Get Free Sample Report

Distribution Channel Segment Analysis

On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacy segment generated a major revenue share of the market in 2023 due to the ease of accessibility and availability of numerous products in retail pharmacies. Moreover, these pharmacists provide detailed instructions to the patient and guide for the dosage and applications of specific medications.

The online pharmacy segment is expected to dominate the market in terms of revenue during the projection period due to its convenience and doorstep delivery. The segment growth is further attributed to the ease of access, cost effectiveness, and availability of a wide range of medicines in online pharmacy.

Regional Outlook

In terms of region, the global allergic bronchopulmonary aspergillosis therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023 due to the presence of a large number of key players and a large patient base in the region. Moreover, rising disposable income and advanced infrastructure to perform a large number of R&D activities boost the market in the region.  

The market in Asia Pacific is projected to grow at a significant pace in the coming years owing to the rising investment in healthcare infrastructure, the presence of a large population in the region, and increasing government initiatives for treating ABPA. For instance,

• The Indian Academy of Pediatrics (IAP) National Respiratory Chapter (NRC) has addressed the need for evidence-based guidelines for managing ABPA in children. Clinical questions relevant to ABPA management have been shortlisted for further study.

About 5% of the total population in India suffers from asthma, increasing the risk for allergic bronchopulmonary aspergillosis and significantly boosting the market.

Get Free Sample Report